Background: Hyperphosphatemia provides relevant and dangerous evidence of end-stage renal disease (ESRD) in patients undergoing periodic hemodialysis. The relationship between hyperphosphatemia and cardiovascular calcification, with the consequences of high morbidity and mortality after cardiovascular events, is well-defined. Hyperphosphatemia is treated by dietary limitation of phosphorus ingestion and by phosphate binders, but only half of ESRD patients fall within the range of K/DOQI guidelines.
H
YPERPHOSPHATEMIA IS a common finding in ESRD patients undergoing conservative treatment or periodic dialysis. It contributes to cardiovascular calcifications and to the high morbidity and mortality of these patients. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Serum phosphorus levels higher than 6.5 mg/dL, a level of calcium/phosphorus products greater than 72 mg 2 /dL 2 , and parathyroid hormone levels higher than 495 pg/mL are each strongly associated with a risk for cardiac mortality in coronary artery disease because of cardiac and vascular calcifications. [10] [11] [12] More than 39% of dialysis patients show phosphorus serum levels higher than 6.5 mg/dL, with a relative mortality risk 27% greater than in patients with phosphorus levels ranging between 2.4 and 6.5 mg/dL. 13 The importance of hyperphosphatemia in the calcification of soft tissues and arteries in ESRD patients was recently reported, and it was also shown that elevated phosphorus plasma levels stimulate phosphorus uptake in smooth muscle cells via Pit-1, a sodium-dependent phosphate cotransporter. Moreover, a simultaneous increase in plasma calcium levels can induce Pit-1 messenger RNA expression. [10] [11] [12] [13] The final consequence is matrix mineralization in tissues, because smooth muscle cells undergo to phenotypic conversion to an osteogenic cell type. 9 To date, the therapeutic treatment of hyperphosphatemia in ESRD patients is based on the dietary limitation of phosphate and on the use of phosphate binders, with a preference for free calcium and a free-metal substance as the polymer sevelamer. However, only half of patients fall within the range of K/DOQI guidelines. Therefore, there is a need to identify other therapeutic approaches to reduce serum phosphate. Since salivary fluid contains phosphate, it is related to daily salivary secretion (1,000 to 1,880 mL), and this mechanism may be considered for the development of a new therapeutic approach to phosphorus removal in ESRD patients.
We summarize the results of our studies to evaluate salivary phosphate excretion in patients undergoing hemodialysis (HD) and with chronic kidney disease (CKD), and the results of interviews in another cohort of HD patients to determine the types and quantities of beverages consumed daily by HD patients, and we report on the amounts of phosphorus in these beverages. These studies sought to evaluate the status of salivary phosphate in HD and CKD patients, and to determine the amount of interference by phosphate in beverages with the phosphate balance of HD patients.
Materials and Methods
We enrolled 68 HD patients, 47 men and 21 women, with a mean age of 61.6 6 9.4 years, on 240-minute bicarbonate dialysis three times a week with polysulphone dialyzers from our nephrology and dialysis units (all values are 6 SEM). Seventy-seven CKD patients, 49 males and 28 females, with a mean age of 63.1 6 20.5 years, were also randomly selected from among outpatients followed by our Nephrology Unit. In these CKD patients, we evaluated creatinine serum levels and glomerular filtration rate (GFR) according to the Modification of Diet in Renal Disease equation. In another study, 155 patients undergoing periodic HD for 240 minutes three times a week, using bicarbonate dialysis and polysulphone dialyzers, were interviewed to identify types of beverages consumed by these patients, with special consideration of the phosphate content of these beverages. A group of healthy subjects was used as a control group for the determination of salivary phosphate. Care was taken to exclude patients with acute infections, malignancy, inflammatory processes, and symptoms of dry mouth, as well as patients with Sjögren syndrome and vegetative nervous system alterations, as previously reported.
14 All patients and control subjects were checked for normal salivary function, using the Saxon test, 15, 16 and were under sevelamer treatment at a dosage of 3200 to 4800 mg daily. The protocol was comprehensive in terms of baseline salivary phosphate secretion and serum phosphorus calcium and parathyroid hormone (PTH) evaluations. Determinations of salivary phosphate secretion were performed before the initiation of hemodialysis treatment and 30 minutes after washing the mouth with deionized water, followed by directly sucking 2 mL of unstimulated saliva up from the oral vestibule, using an automatic pipette. Blood samples for phosphorus and PTH levels were obtained before the first dialysis in the week. Serum and salivary phosphorus levels were determined after centrifugation of a sample by spectrophotometric assay, using a flex reagent cartridge (Dade Behring, Inc., Newark, NJ). Serum PTH concentration was evaluated using the Immulite 2000 intact PTH, solid-phase, two-site chemiluminescent enzyme-labeled immunometric assay (Diagnostic Product Corp., Los Angeles, CA), with normal values ranging from 7 to 53 pg/ mL. The phosphate content of beverages consumed by HD patients was measured in samples of beverages obtained from the market.
Statistical analysis was performed using the Statview II statistical package (Brain Power, Inc., Calabasas, CA). The distribution of data was established by the Kolmogorov-Smirnov test. The nonparametric Wilcoxon-Mann-Whitney rank test sum and regression analysis were used to identify relationships between salivary and serum phosphorus, creatinine, and GFR. A logarithmic transformation of data was performed as necessary, and the results of the fitted model are presented. Analysis of variance was used to evaluate the association of phosphorus serum levels with the types, phosphate content, and quantities of beverages ingested. All data are expressed as geometric means with 95% confidence intervals (95% CIs).
Results
In HD patients, serum and salivary calcium levels were 8.73 (95% CI, 8.49-8.98) mg/dL and 7.21 (95% CI, 6.58-7.91) mg/dL, respectively. Serum and salivary phosphorus levels were 5.56 (95% CI, 5.24-5.91) mg/dL and 30.27 (95% CI, 26.50-34.58) mg/dL, respectively. The level of PTH was 143.63 6 99.41 pg/mL. In control subjects, salivary phosphorus levels were 12.1 (95% CI, 10.58-14.73) mg/dL. According to the confidence intervals, 62 of 68 HD subjects (91.17%) had an increased level of salivary phosphate. In HD patients, salivary phosphorus was significantly higher compared with healthy controls: 30.35 (95% CI, 26.5-34.6) mg/dL, versus 12.1 (95% CI, 10.58-14.73) mg/dL (P , .0001). Multiple regression analysis confirmed that only serum phosphorus was significantly (P , .0001) and independently correlated with salivary phosphorus. In CKD patients, salivary phosphorus was significantly higher compared with controls, at 31.2 mg/dL (95% CI, 10.3-95.6) versus 12.1 (95% CI, 10.58-14.73) mg/dL (P ,.0001). Serum phosphorus was also higher in CKD patients, at 3.70 mg/dL (95% CI, 2.1-6.8) versus 3.50 (95% CI, 2.3-4.6) (P 5 .013). In these patients, salivary phosphorus positively correlated with serum phosphorus (r 5 0.42, P , .0001) and with serum creatinine (r 5 0.71, P , .0001), whereas a negative correlation was found between salivary phosphorus and GFR (r 5 -0.72, P , .0001). No significant correlation between salivary and serum phosphorus, creatinine, and GFR was found in the control group .The 155 HD patients interviewed reported a consumption of red wine, white wine, cola beverages, and beer, i.e., beverages with a higher phosphate content (Table 1) . These beverages were consumed daily by 74.60% of interviewees (Table 1 ). In addition, patients who drank red or white wine, cola beverages, and beer, which contain a higher level of phosphate (Table 2 ), had a serum phosphorus level higher than the range of phosphorus suggested by K/DOQI guidelines (Table 1) . This was related to weekly ingestion of phosphate with beverages (Table 3 ) in these patients. The HD patients who drank orange or lemon juice and mineral water, i.e., beverages with a low phosphorus content, showed phosphorus serum levels within the range of K/DOQI guidelines. No correlation was found with PTH and calcium serum levels.
Discussion
Our data show that HD as well as CKD patients show increased salivary phosphate secretion. In dialysis patients, salivary phosphate secretion may range between 302.7 and 544.86 mg/daily. The relationship between phosphate salivary secretion and GFR likely reflects the possibility of a compensatory activity of salivary glands that increases phosphorus secretion in the presence of impaired renal function. The function of the acini (units of the salivary gland) exhibits a similarity to the function of renal tubules, and studies in animals showed that the concentration of phosphate in plasma is the major factor affecting salivary phosphate secretion. 15 In CKD patients in the present study, as well as in HD patients, 14 the effect of the hypothetical compensatory secretion is abolished by the ingestion of saliva, and its subsequent absorption in the intestinal tract may precipitate a vicious circle between salivary phosphate secretion and fasting phosphate absorption, thereby worsening hyperphosphatemia. The results of this study suggest a potentially important additive therapeutic approach to hyperphosphatemia, by breaking the vicious circle with the absorption of increased salivary phosphate through, for example, salivary phosphate binders. This proposal calls for further investigation.
Our interviews with HD patients indicated that the phosphate content of beverages is not taken into consideration by patients or physicians. In fact, red wine, white wine, cola, and beer, i.e., beverages with a higher phosphate content, are consumed by 74.60% of our HD patients, whereas orange juice, lemonade, and mineral water, i.e., beverages with a lower phosphate content, are consumed by a minority of our HD patients. In addition, patients drinking those beverages with a higher phosphate content exhibited serum phosphorus levels higher than the range suggested by the K/DOQI guidelines. On the other hand, HD patients consuming orange or lemon juice and mineral water, i.e., beverages with low phosphorus content, showed serum levels within the range of K/DOQI guidelines. These data show that beverages represent an important source of phosphate for uremic patients, and could contribute to their hyperphosphatemia and to the poor results obtained with treatments to reduce hyperphosphatemia. The association between patients with higher phosphate serum levels and their consumption of beverages with a greater phosphorus content supports this possibility. The evidence from this study suggests that a dietary prescription for uremic patients (and particularly HD patients) must take into account not only the phosphate intake from food, but also the phosphorus in beverages. Moreover, this evidence may also be considered in the community because of the recent evidence of the role of phosphorus in inducing cardiovascular calcifications also in subjects without renal impairement.
